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Background: Several studies have demonstrated an association between low vitamin D 
levels and cardiovascular risk. Vitamin D cut-off levels are still under debate.
Objectives: To assess two cut-off levels, 40 and 70 nmol/L, respectively, for vitamin D 
measured as 25-hydroxyvitamin D in chest pain patients with suspected acute coronary 
syndrome.
Methods: We investigated 1853 patients from coastal-Norway and inland Northern-
Argentina. A similar database was used for pooling of data. Two-year follow-up data 
including all-cause mortality, cardiac death, and sudden cardiac death in the total patient 
population were analyzed, applying univariate and multivariable analysis.
results: Two hundred fifty-five patients with known vitamin D concentrations died. 
In the multivariable analysis, there was a decrease in total mortality above a cut-off 
level of 40 nmol/L and a decrease in cardiac death above a cut-off level of 70 nmol/L 
[HRs of 0.66 (95% CI, 0.50–0.88), p = 0.004 and 0.46 (95% CI, 0.22–0.94), p = 0.034, 
respectively].
conclusion: Vitamin D cut-off levels of 40 and 70 nmol/L were related to total mortality 
and cardiac death, respectively.
Keywords: vitamin D, acute coronary syndrome, total mortality, cardiac death, cut-off levels, vitamin D deficiency
inTrODUcTiOn
Vitamin D is synthesized in the skin on exposure to UV light, or obtained from the diet, mainly 
from fatty fish (1). Vitamin D deficiency in humans is prevalent and cardiovascular disease (CVD) 
is the primary cause of mortality worldwide (2). Several observational and epidemiological studies 
have demonstrated an association between low levels of vitamin D and (CVD) and mortality (3–8).
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We have previously studied separately two populations, one 
from coastal Norway and one from inland Northern-Argentina, 
with respect to the prognostic significance of vitamin D, measured 
as 25-hydroxyvitamin D [25(OH)D] in acute coronary syndrome 
(ACS). Fish is frequently consumed by the costal population of 
Norway, and is less preferred by the inland beef-consuming popu-
lation in Northern Argentina. At the time of this study, vitamin 
D fortification in food had not been introduced in that country. 
Furthermore, the subtropical location of Salta, Argentina, is 
associated with a higher exposure to sun in comparison to that of 
the temperate location of Norway. Our two patient populations 
were divided into 25(OH)D quartiles, comparing patients with 
high and low levels of vitamin D. We found that vitamin D was 
an independent prognostic biomarker in relation to total mortal-
ity and cardiac death in the Argentinean population, whereas in 
the Norwegian population its prognostic utility was less evident, 
but with a clear trend supporting the findings obtained in the 
Argentinean study (9, 10).
Optimal and exact cut-off levels of vitamin D are still under 
debate (8, 11–13). Additionally, studies have shown that high 
levels of vitamin D are also associated with increased mortality 
(3, 14).
In the present study, we have pooled our two populations and 
grouped them according to gender, in order to better assess the 
prognostic significance of 25(OH)D according to (1) 25(OH)D 
groups and (2) two cut-off values. We have added information 
based on a healthy blood donor population from both countries 
in order to obtain a reference value for vitamin D.
MaTerials anD MeThODs
study Design and Patient Population
Participants in the present analysis were pooled from two studies, 
both designed to evaluate the prognostic utility of serum 25(OH)
D status in patients with chest pain and ACS.
The RACS study (Risk Markers in the Acute Coronary 
Syndrome) (ClinicalTrials.gov NCT00521976) was a single-
center prospective observational study in which 871 patients with 
chest pain and suspected ACS were consecutively admitted to the 
Stavanger University Hospital from November 2002 to October 
2003.
The ARgentinean Risk Assessment Registry in the Acute 
Coronary Syndrome, the “ARRA-RACS Study” (Ref. Clinical 
Trial.gov identifier: NCT01377402), was performed at nine 
hospitals in the Province of Salta, Northern Argentina, in which 
982 patients with chest pain and suspected ACS were hospitalized 
from December 2005 to January 2009.
The details, including blood sampling procedures, laboratory 
measurements, and exclusion criteria of the RACS and ARRA-
RACS studies, have been published previously (9, 10, 15).
The primary outcome in both studies was 2-year all-cause 
mortality, and the secondary outcomes included cardiac death 
and sudden cardiac death (SCD). The population was divided into 
three groups according to the following 25(OH)D: ≤40 nmol/L, 
between >40 and ≤70 nmol/L, and >70 nmol/L, and two cut-
off levels; ≤40 nmol/L and ≤70 nmol/L. The prognostic impact 
within the suggested 25(OH)D levels was analyzed applying 
univariate and multivariable analysis.
The blood bank study included blood samples from 86 healthy 
individuals, with an equal number of males and females, recruited 
from the blood bank in Stavanger, Norway, and 104 healthy indi-
viduals (53 females and 49 males) recruited from two blood banks 
in Salta, Argentina. Their information was treated anonymously.
25(OH)D measurements were carried out at the Department 
of Medical Biochemistry at Stavanger University Hospital, as 
previously described (9).
sTaTisTical analYsis
Patients were divided into three categories according to their 
25(OH)D levels. Results are presented for the complete 2-year 
follow-up period and after censoring the events in the first 
3  months (91  days). Approximately, normally distributed 
variables were given as mean and standard deviation (SD) within 
vitamin D groups. The Chi-square test for association was applied 
between the 25(OH)D and categorical variables at baseline. The 
one-way ANOVA was used to test for the equality of means of 
scale variables (e.g., age) among vitamin D categories and the 
two-sample t-test was used for comparing means of two samples. 
Stepwise Cox multivariable proportional hazards regression 
models with total death, cardiac death, and SCD, as the dependent 
variable, and 25(OH)D categories and other variables as potential 
independent predictors (listed below) were fitted. To examine the 
differences in prognosis between subjects in the higher vs. the 
lowest 25(OH)D group, we adjusted for gender, age, smoking, 
hypertension, index diagnosis, diabetes mellitus, congestive heart 
failure (CHF) [defined by Killip–Kimball class (16) at admis-
sion; patients in classes 2–4 were classified as CHF patients and 
patients in class 1 were classified as non-CHF], history of previous 
coronary heart disease (i.e., history of either angina pectoris, MI, 
coronary artery bypass graft, or percutaneous coronary interven-
tion), hypercholesterolemia/use of statins, TnT >  0.01  ng/mL, 
estimated glomerular filtration rate, high sensitivity C-reactive 
protein, B-type natriuretic peptide, body mass index (BMI) 
(kg/m2), month of sampling, country, and use of betablockers 
prior to enrollment. The hazard ratios (HRs) are presented with 
95% confidence interval (CI). The Kaplan–Meier product limits 
were used for plotting time-to-event and the log-rank test was used 
to compare survival curves across 25(OH)D groups. The added 
prognostic value by including 25(OH)D levels to the significant 
confounders in the Cox regression model was assessed by using 
the log-likelihood test. The statistical analyses were performed 
using the statistical package SPSS version 19.0. All tests were two 
sided with a significance level of 5%. Highly significant differences 
were based on a two-tailed significance level of 1%.
eThics sTaTeMenT
The RACS study was approved by the Regional Board of Research 
Ethics and the Norwegian Health Authorities and conducted 
in accordance with the Helsinki Declaration of 1971, as revised 
in 1983.
TaBle 1 | Baseline characteristics according to 25(Oh)D concentrations at admission in the total patient population.
concentrations of 25(Oh)D
characteristics n (%) ≤40 nmol/l 40–70 nmol/l >70 nmol/l p-value
Mean 25(OH)D (nmol/L)a 31.6 ± 6.0 54.2 ± 8.1 82.4 ± 12.4 <0.001
Age, yearsa 68.3 ± 14.2 64.5 ± 14.4 64.9 ± 14.0 <0.001
Male, n (%) 255 (49.4) 677 (63.9) 180 (68.2) <0.001
Smoking status, n (%) 0.50
Current smoker, n (%) 139 (27.3) 264 (25.2) 61 (23.3)
Past smoker, n (%) 243 (47.6) 484 (46.1) 122 (46.7)
Never smoked, n (%) 128 (25.1) 301(28.7) 78 (29.9)
Angina pectoris, n (%) 161 (31.2) 349 (32.9) 88 (33.3) 0.75
CHF, n (%)
Killip classes 2–4 156 (30.2) 189 (17.8) 52 (19.7) <0.001
History of previous MI, n (%) 124 (24.0) 205 (19.3) 52 (19.7) 0.09
CABG, n (%) 38 (7.4) 76 (7.2) 20 (7.6) 0.97
PCI, n (%) 50 (9.7) 106 (10.0) 29 (11.0) 0.85
Hypertension, n (%) 296 (57.4) 553 (52.2) 145 (54.9) 0.14
History of DM 1, n (%) 9 (1.8) 12 (1.1) 2 (0.8) 0.43
History of DM 2, n (%) 117 (22.9) 155 (14.7) 26 (9.9) <0.001
STEMI, n (%) 71 (13.9) 166 (15.8) 35 (13.3) 0.45
TnT release, n (%) 255 (49.4) 476 (44.9) 123 (46.6) 0.25
eGFR (μmol L−1)a 71.4 ± 29.3 74.4 ± 26.0 68.0 ± 23.8 0.001
Cholesterol/statin, n (%) 157 (30.4) 326 (30.8) 100 (37.9) 0.07
Beta-blocker, n (%) 157 (30.7) 323 (30.7) 81 (31.0) 0.99
Known CHD, n (%) 243 (47.4) 497 (47.0) 126 (47.9) 0.97
BMI (kg/m2)a 27.0 ± 5.0 27.1 ± 4.4 25.8 ± 3.9 <0.001
BNP quartiles <0.001
Q1 111 (21.9) 270 (26.0) 72 (28.1)
Q2 98 (19.3) 288 (27.7) 64 (25.0)
Q3 138 (27.2) 252 (24.2) 61 (23.8)
Q4 160 (31.6) 230 (22.1) 59 (23.0)
hsCRP quartiles 0.009
Q1 105 (20.4) 281 (26.5) 76 (28.8)
Q2 114 (22.2) 271 (25.6) 70 (26.5)
Q3 144 (28.0) 256 (24.2) 61 (23.1)
Q4 151 (29.4) 251 (23.7) 57 (21.6)
Country 0.002
Argentina 284 (55.0) 582 (54.9) 114 (43.2)
Norway 232 (45.0) 478 (45.1) 150 (56.8)
aMean ± SD.
SD, standard deviation 25(OH)D, 25-hydroxyvitamin D; CHF, congestive heart failure; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous coronary 
intervention; DM, diabetes mellitus; STEMI, ST-elevation myocardial infarction; TnT, troponin T; eGFR, estimated glomerular filtration rate; CHD, coronary heart disease; BMI, body 
mass index; BNP, B-type natriuretic peptide; hsCRP, high sensitivity C-reactive protein.
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The ARRA-RACS study was approved by the Ethics 
Committee at the Board of Medical School of Salta and conducted 
in accordance with the Helsinki Declaration of 1971, as revised 
in 1983. At San Bernardo Hospital and Sanatorio El Carmen, 
the study was also approved by the local Ethics Committee and 
Institutional Review Board of San Bernardo Hospital and the 
Institutional Review Board of Sanatorio El Carmen, respectively. 
The Norwegian biobank containing Argentinean blood samples 
was approved by the Regional Board of Research Ethics and 
the Norwegian health authorities. This study was monitored by 
Stavanger Health Research, Stavanger, Norway.
The blood bank study was approved by the Regional Board of 
Research Ethics.
Written informed consent was obtained from all patients in 
all three studies.
resUlTs
A total of 1853 (60% males and 40% females) patients were included 
in the study; 982 from Argentina and 871 from Norway. Samples 
for 25(OH)D analysis were not available for 2 Argentinean and 10 
Norwegian patients, and 1 implausibly high 25(OH)D value for a 
Norwegian patient was ignored. Four Argentinean patients with 
known 25(OH)D values were lost to follow-up and, hence, their 
mortality status is unknown. Thus, both survival and 25(OH)D 
values are known for 1836 (976 Argentinean and 860 Norwegian) 
patients.
Mean age (±SD) in the combined patient population was 
65.7 ± 14.3 (males 63.0 ± 14.2 years and females 69.8 ± 13.5 years). 
Mean 25(OH)D levels were 51.9 ± 18.0 nmol/L in the total patient 
population, 54.1 ± 17.9 nmol/L in males and 48.4 ± 17.5 nmol/L 
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FigUre 1 | Kaplan–Meier survival curves for all-cause mortality in the three 25(Oh)D groups for all patients.
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in females. The baseline characteristics according to 25(OH)D 
concentrations at admission in the total patient population are 
shown in Table 1.
Prognosis estimates related to Different 
Vitamin D concentrations
After a 2-year follow-up, 255 patients with known 25(OH)D 
values had died. Of these, 150 deaths were caused by a cardiac 
event, of whom, 75 patients died suddenly.
Kaplan–Meier survival curves for all-cause mortality in three 
25(OH)D groups are presented in Figure  1. Receiver-operated 
characteristics (ROC) curve for 25(OH)D for all-cause mortality 
is shown in Figure 2. The area under the ROC for 25(OH)D was 
0.619 (p < 0.001). Using 40 nmol/L as threshold, the sensitivity 
was 0.435 and specificity was 0.744. Using 70 nmol/L as threshold, 
the sensitivity was 0.898 and specificity was 0.150.
In the univariate Cox regression analysis, there was a highly 
statistically significant difference between the upper (>70 nmol/L) 
and middle (40–≤70  nmol/L) as compared to the lowest group 
of 25(OH)D with respect to all-cause mortality, cardiac death, 
and SCD. These findings were maintained for total death in the 
multivariable Cox regression analysis, with HRs of 0.56 (95% CI, 
0.34–0.92), p = 0.021 and 0.69 (95% CI, 0.51–0.92), p = 0.013 in the 
upper groups, respectively. However, for cardiac death and SCD, the 
difference in prognosis was significant only when comparing the 
upper with the lowest group, with HRs of 0.41 (95% CI, 0.19–0.87), 
p = 0.021 and HR of 0.23 (95% CI, 0.05–0.96), p = 0.044, respectively.
Similar results were obtained for total mortality and cardiac 
mortality after censoring the first 3 months. The univariate and 
multivariable HRs for 25(OH)D groups for the complete follow-
up and after censoring the first 3 months are presented in Tables 2 
and 3, respectively.
Adding 25(OH)D levels to the significant confounders 
improved the prognostic value of the Cox regression model, using 
the censored values for both all-cause mortality [χ2(2) = 9.723; 
p = 0.008] and cardiac death [χ2(2) = 7.647; p = 0.022].
Prognosis estimates Based on set cut-Off 
Values of Vitamin D
In the multivariable analysis, there was a statistically significant 
decrease in all-cause mortality in the population with 25(OH)D 
level above 40 nmol/L as compared to those with a level below 
or equal to 40 nmol/L, with a HR of 0.66 (95% CI, 0.50–0.88), 
p = 0.004, whereas no significant difference was found in relation 
to cardiac and SCD. Furthermore, these differences were main-
tained when assessing the total population according to gender.
In the multivariate analysis, we also noted a statistically 
significant decrease in cardiac death in patients with 25(OH)D 
levels above 70 nmol/L as compared to those with levels equal 
to or below 70 nmol/L, with a HR of 0.46 (95% CI, 0.22 – 0.94), 
p = 0.034, whereas no significant difference was found in relation 
to total mortality and SCD. Furthermore, no significant differ-
ences were found when assessing the total population according 
to gender.
Blood Donors From argentina and norway
Mean age of the total blood donor group (n  =  190) was 
46.0 ±  10.3  years. There were 96 females with a mean age of 
46.1 ± 10.4 years, and a 25(OH)D level of 59.7 ± 21.5 nmol/L. The 
mean age of the male population (n = 94) was 46.0 ± 10.3 years, and 
this gender presented with a 25(OH)D level of 55.3 ± 18.2 nmol/L. 
No gender differences in 25(OH)D levels were found in this nor-
mal population. Values for the separate countries are presented 
in Table 4.
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FigUre 2 | receiver-operated characteristics curve for 25(Oh)D for all-cause mortality.
TaBle 2 | The univariate and multivariable hrs (95% ci) for groups of 
25(Oh)D for the complete 2-year follow-up.
Univariate analysis
>70 vs. ≤40 nmol/l
Multivariable analysis
>70 vs. ≤40 nmol/l
Total mortality 0.43 (0.28–0.66), p < 0.001 0.56 (0.34–0.92), p = 0.021
Cardiac death 0.33 (0.17–0.62), p = 0.001 0.41 (0.19–0.87), p = 0.021
SCD 0.16 (0.05–0.52), p = 0.002 0.23 (0.05–0.96), p = 0.044
Univariate analysis
40–≤70 vs. ≤40 nmol/l
Multivariable analysis
40–≤70 vs. ≤ 40 nmol/l
Total mortality 0.49 (0.38–0.64), p < 0.001  0.69 (0.51–0.92), p = 0.013
Cardiac death 0.57 (0.41–0.80), p = 0.001 0.83 (0.56–1.23), p = 0.35
SCD 0.51 (0.32–0.81), p = 0.005 0.23 (0.05–1.32), p = 0.32
SCD, sudden cardiac death.
TaBle 3 | The univariate and multivariable hrs (95% ci) for groups of 
25(Oh)D after censoring events in the first 3 months of follow-up.
Univariate analysis
>70 vs. ≤40 nmol/l
Multivariable analysis
>70 vs. ≤40 nmol/l
Total mortality 0.33 (0.18–0.58), p < 0.000 0.38 (0.19–0.74), p = 0.005
Cardiac death 0.24 (0.09–0.60), p = 0.002 0.26 (0.08–0.85), p = 0.027
SCD 0.23 (0.07–0.78), p = 0.010 0.39 (0.09–1.71), p = 0.210
Univariate analysis
40–≤70 vs. ≤40 nmol/l
Multivariable analysis
40–≤70 vs. ≤40 nmol/l
Total mortality 0.48 (0.35–0.66), p < 0.000 0.69 (0.49–0.97), p = 0.033
Cardiac death 0.60 (0.39–0.91), p = 0.016 0.96 (0.60–1.55), p = 0.88
SCD  0.47 (0.27–0.84), p = 0.10 0.86 (0.45––1.62), p = 0.63
SCD, sudden cardiac death.
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DiscUssiOn
As optimal and exact cut-off levels of vitamin D are still under 
debate, we have addressed this issue in the present analysis and 
studied the prognostic value of vitamin D cut-off values of 40 
and 70 nmol/L, respectively, in a pooled ACS suspected patient 
population from inland Argentina and coastal-Norway, applying 
univariate and multivariate analyses. Furthermore, survival was 
compared for patients with vitamin D levels ≤40 nmol/L, >40 
to ≤70  nmol/L, and >70  nmol/L, respectively. The proportion 
of total-, cardiac- and SCD decreased significantly with increas-
ing vitamin D levels in the univariate analysis. This pattern 
was maintained for total death in the multivariable analysis, 
whereas cardiac death and SCD differed only when comparing 
the highest to the lowest group. Adding 25(OH)D levels to the 
significant confounders improved the prognostic value of the Cox 
regression model.
We chose a cut-off level of 40 nmol/L for vitamin D, based on a 
report by Ross et al (12), claiming that a vitamin D concentration 
above this level will meet the needs of 50% of the population. 
As demonstrated previously (10), patients in the lower vitamin 
D group had a significant lower survival rate than those with 
levels above 40  nmol/L. These differences were maintained 
when assessing the total population according to gender. In our 
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norway 25(Oh)D (nmol/l) argentina 25(Oh)D (nmol/l) Total population 25(Oh)D (nmol/l)
Total (n = 86) 62.4 ± 22.1 Total (n = 104) 53.5 ± 17.2 Total (n = 190) 57.5 ± 20.0
Age < 50 (n = 50) 59.4 ± 21.6 Age < 50 (n = 53) 51.4 ± 17.3 Age < 50 (n = 103) 55.3 ± 19.8
Age ≥ 50 (n = 36) 66.5 ± 22.5 Age ≥ 50 (n = 49) 55.2 ± 17.1 Age ≥ 50 (n = 85) 60.0 ± 20.2
Females (n = 43) 66.1 ± 22.6 Females (n = 53) 54.5 ± 19.3 Females (n = 96) 59.7 ± 21.5 
Males (n = 43) 58.6 ± 21.2 Males (n = 51) 52.5 ± 14.9 Males (n = 94) 55.3 ± 18.2
population, 28% of the patients had vitamin D levels below or 
equal to 40 nmol/L. Patients in the lower level vitamin D group 
were older, had higher BMI, and were sicker as judged by a higher 
rate of heart insufficiency and diabetes as compared to patients in 
the higher vitamin D group. As suggested by the US Endocrine 
Society, levels below 50 nmol/L are defined as deficiency/insuf-
ficiency and levels above 75  nmol/L are regarded as sufficient 
(13). Accordingly, we chose a second cut-off level of 70 nmol/L 
and above this level we demonstrated a statistically significant 
reduced HR of cardiac death.
It has previously been reported that also high concentrations 
of 25(OH)D are associated with elevated risks of overall mortality 
(3, 14), but this relationship was not noted in the present study.
Vitamin D measurements were performed in blood samples 
obtained at admission, as close as possible to the index event, 
decreasing the possibility of a fall of vitamin D during hospitaliza-
tion and reconvalescence. Mean vitamin D levels in our study 
patient population were similar to that of a healthy blood donor 
population, suggesting that low vitamin D levels are not necessar-
ily secondary to patients’ health status. The similarity in vitamin 
D status between patients and healthy individuals may support 
the utility of vitamin D as a primary predictor of future outcome 
in our ACS patient population.
With the applied cut-off levels of 40 and 70 nmol/L, the sen-
sitivity and specificity favors the use of the former cut-off level, 
demonstrating a sensitivity of 0.435 and specificity of 0.744, 
whereas a cut-off level of 70 nmol/L is associated with a sensitivity 
of 0.898 and a low specificity of 0.150.
Strengths consist of an unselected chest pain population with 
suspected ACS and a relatively short follow-up time of 2 years.
Limitations have previously been described (9, 10) and consist 
mainly of one set of blood samples at admission and no measure-
ments of parathyroid hormone. As this is an observational study, 
unknown and residual confounders may have been missed. The 
“parent” studies RACS and ARRA-RACS were performed in two 
countries in different hemispheres with different sun exposure 
and dietary habits. Lifestyle confounders, including physical 
activity, exposure to sunlight, diet, and alcohol consumption are 
difficult to measure and could potentially influence the results. 
Furthermore, reverse causation is inherent in an observational 
study; thus, vitamin D concentrations could simply be an indica-
tor of chronic disease or a marker of a lifestyle. Although blood 
samples were drawn in each country, vitamin D analysis was 
performed by one biochemist at the Department of Medical 
Biochemistry at Stavanger University Hospital.
In conclusion, we noted an increased rate of total mortality 
with a level of vitamin D below 40 nmol/L and increased cardiac 
mortality was found to be related to vitamin D levels below 
70 nmol/L. The results might have practical implications in terms 
of prophylactic vitamin D treatment in subjects at high risk of 
coronary heart disease, but we need randomized intervention 
studies to assess whether vitamin D supplementation reduces 
mortality and CVDs.
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